Was It Anxiety—or Was ADHD Missed? ADHD in Women

Anxiety can scatter attention. So can depression, trauma, poor sleep, and ADHD. The timeline, settings, and real-life cost help show whether ADHD was missed—and whether more than one condition needs care.

When worry is not the whole story

Zoom

Fictional composite; not a real patient.

Maya is 39 and arrives everywhere early. She checks her calendar six times before lunch. Her desk looks calm because she stays late to reset it.

Therapy helped her panic. Yet she still loses invoices, misses small steps, and freezes before simple tasks. She wonders whether anxiety is the whole story.

That question deserves more than a quiz. It also deserves more than a quick “yes.” ADHD can be missed in women. Anxiety, depression, trauma, autism, sleep problems, and medical issues can also affect focus. They may occur with ADHD, not only instead of it.

What this guide covers — and what it deliberately does not. It covers why ADHD may be missed in women, what a sound adult evaluation includes, and the benefits and limits of common treatments. It deliberately does not provide general anxiety or depression treatment, diagnose from a symptom list, or replace the broader adult ADHD services page.

ADHD is a pattern across time

Attention-deficit/hyperactivity disorder, or ADHD, is a neurodevelopmental condition. “Neurodevelopmental” means its pattern begins while the brain is developing. An adult diagnosis should trace symptoms to before age 12. The pattern must persist, impair life, and appear across more than one setting.[1,2]

This matters because current stress can look similar. A bad month at work may bring missed details and poor sleep. Grief can make thinking slow. Depression can drain energy. None of those experiences proves ADHD.

An adult may first receive the diagnosis at 30, 45, or later. That does not mean ADHD began then. It means the earlier pattern was not recognized, was managed with great effort, or became harder to contain.

The cost also matters. A person may keep a job and still spend every evening repairing mistakes. She may pay late fees, avoid mail, lose sleep before deadlines, or depend on rigid systems. Visible success does not erase impairment.

The same pattern can look different as life changes. A child may rely on parents, bells, and short assignments. A college student must plan long projects alone. A new parent may suddenly manage feeding, school forms, appointments, and work. The setting did not create ADHD, but it may expose a pattern that earlier support held together.

Look for repeated themes rather than one dramatic example. A person may always underestimate travel time, forget the middle step, or need a deadline to begin. She may function well in a clear job and struggle at home, where tasks have no fixed start. That still counts as more than one part of life when the wider history supports it.[2]

Why ADHD may be missed in women

Girls and women can be recognized later. Referral systems often notice behavior that disrupts a classroom or home. Quiet inattention, internal pressure, and elaborate coping systems can draw less attention.[3,4]

That does not create a separate “female ADHD.” The diagnosis is the same. Nor does every woman mask symptoms, seem calm, or mainly struggle with inattention. Stereotypes can miss women in both directions.

Gender roles may hide the pattern. A parent may carry the household calendar, school messages, meals, and appointments. More responsibility can expose old difficulty with time and working memory. It can also create overload in someone without ADHD.

The useful question is not, “Do I look like the usual picture?” It is, “What has the pattern been across my life?” School comments, repeated deadline problems, unfinished projects, driving history, and money mistakes can add context. Old records can help, but their absence does not automatically rule out ADHD.

Compensation can be costly. Someone may set five alarms, arrive an hour early, or work late so no one sees unfinished tasks. These systems can protect a grade or paycheck while using nearly all available energy.

Ask what happens when the system breaks. Travel, illness, a new baby, a promotion, or loss of help may reveal how much support was doing. That information can explain late recognition without claiming that ADHD began in adulthood.

Bias and access also shape who gets assessed. A quiet student may receive praise for not causing trouble while missing much of the lesson. Another girl may be labeled careless or overly emotional. These possibilities are reasons to ask better questions, not proof that every missed problem was ADHD.[3,4]

Anxiety, depression, and ADHD can overlap

Poor focus is not a diagnosis. Neither is restlessness, procrastination, irritability, or feeling overwhelmed. These experiences cross many conditions.[1,2,5]

ADHD often shows a long pattern of difficulty with time, organization, starting, finishing, and impulse control. Anxiety may pull attention toward threat and worry. Depression may bring low mood, lost interest, low energy, and slowed thinking. Trauma can produce alertness, avoidance, or memory trouble.

The conditions can also coexist. Treating panic may help panic while task problems remain. Treating ADHD may improve organization while depression still needs care. A good assessment does not force an either-or answer when both fit.

Course gives clues. ADHD is usually steady across years, even when demands change its visibility. Mania is more episodic. It may include unusually high or irritable mood, far less need for sleep, racing thoughts, grand plans, or risky behavior. That is not simply “very intense ADHD.”

Urgent distinction: New loss of reality testing, possible mania, overdose, severe stimulant intoxication, chest pain, fainting, seizure, or imminent danger needs emergency care. Call 911 or go to an emergency department; do not use an online checklist to sort it out.[6]

What a proper adult evaluation includes

A sound evaluation is a process, not a score. It begins with current symptoms and the ways they affect daily life. It then moves backward through childhood and forward across settings.[2]

A clinician may ask about:

• school performance, comments, behavior, and learning needs;
• work, home, relationships, money, driving, and self-care;
• when symptoms first appeared and when they became impairing;
• anxiety, depression, bipolar symptoms, trauma, obsessive symptoms, and substance use;
• autism, learning differences, eating concerns, and sleep;
• medical conditions, hormones, medicines, and supplements;
• family history and prior treatment response.

Collateral information means useful observations from another person or record. It can support the history when it is available and safe to obtain. It should not become an impossible gate for an adult who lacks report cards or family contact.

The assessment should also name goals. “Focus better” is hard to measure. “Pay bills on time,” “finish charting before leaving work,” or “reduce unsafe driving choices” gives treatment a clear target.

It helps to prepare a short timeline before the visit. Write down two childhood examples, two current settings, and the cost of each problem. Add sleep, mood, substance, and medicine history. This keeps the visit focused without turning it into a performance.

A strong clinician should be able to explain the reasoning. Ask what supports ADHD, what argues against it, and which facts remain unclear. Ask whether another condition may be present too. A careful answer may be more useful than instant certainty.

One visit may not settle every question. Records can arrive later, sleep may need review, or mood symptoms may need safer control first. A staged assessment can still be thorough when the plan and next decision are clear.[2]

What tests can—and cannot—decide

Rating scales can organize symptoms. They can also track change. They cannot confirm ADHD alone. A brain scan, blood test, neuropsychological test, caffeine response, or medication response cannot settle the diagnosis by itself.[2,5]

Computerized attention tasks may look objective. Yet attention changes with sleep, anxiety, motivation, pain, and the testing setting. A 2024 systematic review found the Conners Continuous Performance Test-3 was a weak or poor stand-alone predictor in several included studies. The authors recommended using multiple measures.[8]

This does not make testing useless. A test may describe attention, speed, memory, or learning. It may help answer a focused question. Its role is to add evidence, not overrule the life history.

The same limit applies to online quizzes. A high score may help someone find words for a concern. It can also reflect worry, poor sleep, pain, grief, or another cause. Bring the result if it helps, but bring real examples with it.

Do not use a friend’s diagnosis as a test either. Shared traits can begin a useful conversation, yet similar behavior can come from different paths. The assessment must still connect symptoms to childhood, settings, impairment, and alternatives.[1,2,5]

Be cautious when an evaluation promises certainty from one device. Be equally cautious when one normal test is used to dismiss years of impairment. The diagnosis comes from the whole pattern.

Hormones are a clue, not a dosing plan

Some women report changes in attention or emotional control around puberty, the menstrual cycle, pregnancy, postpartum, or menopause. Those reports deserve respectful attention.

The research is still small. A 2025 systematic review found only 11 diverse studies on ADHD and sex hormones in females. Methods and measures varied, and the review found no empirical studies of ADHD during menopause.[9]

That means two things can be true. A person’s pattern may feel real and useful to track. Science still cannot support one hormone explanation or a universal cycle-based medication plan.

Tracking may help a clinician see whether symptoms change with bleeding, sleep, pain, mood, or life demands. It may also reveal premenstrual mood symptoms, migraine, anemia, or another issue. A pattern is information. It is not a prescription.

A simple record is enough. Note the date, sleep, bleeding, pain, mood, focus, and major demands. Use the same brief scale each day when possible. A few remembered bad days cannot show whether the pattern repeats.

Tracking should make care clearer, not become another burden. Stop if it fuels fear or takes too much time. The goal is to bring a usable pattern to a clinician, not to prove a theory before the visit.[9]

Do not adjust stimulant timing or dose from a social-media chart. Bring the pattern to the clinician who knows your diagnosis, health history, and other medicines.

Treatment works best when tied to goals

For adults with a confirmed diagnosis, stimulants and atomoxetine can reduce core symptoms over the short term. Evidence is stronger for symptom change than for long-term quality of life and daily function.[10]

Medication is not a diagnostic trial. Feeling calmer on a stimulant does not prove ADHD. Feeling anxious on one dose does not rule it out. Response and side effects help guide treatment after the diagnosis is sound.

Structured cognitive behavioral therapy, often called CBT, can also help. It teaches practical ways to plan, begin tasks, manage time, and respond to setbacks. A 2026 analysis found modest improvement in core symptoms and executive skills. Effects on anxiety and depression were smaller, and quality-of-life benefit was not clear.[11]

Practical supports may include written instructions, visible deadlines, fewer handoffs, a quieter workspace, or breaking a large task into named steps. Their value should be judged by function. The goal is not to build a perfect planner. It is to make important parts of life safer and more workable.

A treatment trial needs a start point and a review date. Choose two or three targets before changing the plan. Record enough to compare benefit, side effects, sleep, and daily function. More focus with no better function may not be a meaningful win.

Care can also change the environment. Written follow-up may reduce missed details. A shared family calendar may lower memory load. Body doubling, timers, and task lists help some people. None is a required sign of ADHD, and none works for everyone.

When anxiety or depression also needs care, priorities may shift. The safest first step depends on severity, function, past response, and risk. Treating one condition does not make the other unreal.[10,11]

Medication safety needs the whole picture

Stimulants carry risks of misuse, sharing, addiction, and overdose. They should be taken only as prescribed and stored where other people cannot access them.[6]

ADHD medicines can also change heart rate or blood pressure. Average changes in trials were small, but averages do not rule out individual problems or rare events.[12] A medication visit should consider cardiac history, fainting, chest symptoms, blood pressure, sleep, appetite, mood, substance use, and other medicines.

Monitoring is not punishment. It helps answer three basic questions:

1. Is the medicine improving the agreed target?
2. Is the benefit large enough to matter?
3. Are side effects or risks changing the plan?

Bring the exact dose, time taken, and duration to follow-up. Also report appetite, sleep, headaches, mood shifts, alcohol or cannabis use, and any extra doses. A clear record helps separate a brief side effect from a pattern that needs change.

Never lend medication or use someone else’s supply. Store it away from children, visitors, and anyone at risk for misuse. If pills are lost, stolen, or taken incorrectly, contact the prescriber or pharmacist instead of replacing doses on your own.[6]

Seek urgent help for chest pain, fainting, seizure, severe agitation, hallucinations, overdose, or fear that someone may be harmed. Do not drive yourself if you are impaired.

Pregnancy and breastfeeding need drug-specific decisions

There is no honest class-wide answer to “Are ADHD medicines safe in pregnancy?” Large observational studies are broadly reassuring about major overall malformations. They cannot prove that every drug or pregnancy is risk-free. Methylphenidate has had a possible small cardiac-malformation signal in pooled data.[13]

Another large study found small associations with some placental or preterm outcomes. Absolute differences were small, and the design could not prove causation.[14] Two adjusted cohorts have also been reassuring about child neurodevelopment after prescribed stimulant exposure, but they cannot settle every drug, dose, timing, or rare outcome.[15,16]

The decision should include the risk of untreated impairment. For some people, severe inattention affects driving, work, nutrition, or prenatal care. Others may manage with different supports. Do not stop or change medication suddenly because of an article.

Useful questions include: Which drug has the best evidence for this stage? What benefit would justify exposure? What changes if the medicine is stopped? How will blood pressure, sleep, appetite, fetal growth, or infant feeding be followed when relevant?

Preconception review gives more time for those choices. An unplanned pregnancy still deserves calm, prompt review rather than panic. Confirm the medicine, dose, timing, and actual exposure before drawing conclusions from a class-wide headline.[13–16]

Breastfeeding evidence is specific to each drug. Limited methylphenidate reports found low milk levels and no reported adverse effects in those small cases.[17] The same source notes methylphenidate may lower prolactin, which could reduce milk supply, especially early in breastfeeding.[17] A 2026 atomoxetine milk study found low transfer, but infant blood levels and long-term outcomes remain sparse.[18]

Low milk transfer is not the same as proven infant safety. Infant age, prematurity, feeding, sleep, growth, and the parent’s functioning all belong in the discussion.

SIMTRIYO was not yet a current option at this review

FDA listed SIMTRIYO, or centanafadine, in its 2026 novel-drug records and issued a letter dated July 24, 2026. The approval covers ADHD in adults and in children 6 years and older who weigh at least 20 kg. The letter also said approval would become effective when the Drug Enforcement Administration published interim scheduling.[7]

The manufacturer expected commercial availability after scheduling later in 2026. No scheduling notice or commercial launch was verified by August 15, 2026. That makes “newly available now” inaccurate at this review.

Centanafadine is labeled as a norepinephrine, dopamine, and serotonin reuptake inhibitor. It is also labeled a central nervous system stimulant. It should not be marketed as a proven safer “non-stimulant.”

The newness matters. There is no mature real-world safety record or comparative effectiveness evidence. FDA also required pregnancy and lactation studies after approval.

For the full picture — dosing, trial results, the two boxed warnings, and why no pharmacy can fill it yet — see Simtriyo (Centanafadine): What the New ADHD Medication Is.

Bring this checklist to an evaluation

Bring what you can. Missing records do not end the conversation.

Before you leave the visit

Ask the clinician to sum up what fits, what does not fit, and what still needs more work. That brief recap can keep a hard visit from turning into a blur.

If ADHD seems likely, ask which facts show that the pattern began in youth and crossed more than one part of life. If it does not seem likely, ask what else could explain the same signs.

Write down the next step before you leave, since “follow up later” can be hard when time and task skills are strained. The next step might be one form, one call, one sleep check, or one visit.

Ask who will review old records if they arrive and how you can add facts without starting the whole process again. A clear route can cut down on lost notes and repeat work.

If a drug is part of the plan, name the goal in plain words and choose a date to check it. “I will turn in work on time” is more useful than “I will feel fixed.”

Ask what side effects can wait for a call, what needs same-day help, and what needs the emergency room. Put that answer in the same place as the drug list.

If no drug is used, ask which supports can start now and how their effect will be judged. A tool is worth keeping when it helps real work, not just when it looks neat.

Share the plan with one trusted person when that feels safe, since they may spot gains or harms you miss. They should not become the judge of your worth or the sole source of proof.

Plan for what happens when the first step fails, because one poor fit does not settle the diagnosis or predict all care. A sound plan leaves room to learn and change course.

Keep your own copy of the goals, the next date, and the reason for each choice. This makes the next talk faster and helps the care team compare the same facts.[2,10,11]

At home, keep the plan where you already look, rather than build a new system that may soon fade from view. Use one note for doses, sleep, key tasks, and side effects, so the facts stay close when the next visit comes.

Pick one week that is fairly typical before you judge the plan, unless a harm or sharp change calls for help sooner. Mark a simple yes or no for the goal each day, since a long journal may be hard to keep.

If the plan helps at work but harms sleep, both facts count and should shape the next choice. If it helps focus but not bills, missed meals, or safe driving, ask whether the goal or plan needs to change.

Good care should leave you with less shame and more clear next steps, even when the answer takes time. The aim is not to prove a label; it is to find what makes day-to-day life work with less cost.

Use the visit to ask process questions. How will childhood onset be assessed? Which other explanations need review? How will benefit and harm be measured? What happens if the first plan does not help?

When symptoms need faster help

Routine assessment fits a long-standing pattern with stable safety. Ask for prompt review when function is worsening, sleep is collapsing, substance use is rising, or medicine is causing major problems.

Possible mania, psychosis, severe agitation, intoxication, or inability to function safely needs same-day assessment. Imminent self-harm or other-harm, overdose, loss of control, seizure, severe chest pain, fainting, or sudden neurologic change is an emergency.

For immediate danger, call 911 or go to an emergency department. A crisis line can help connect care when there is no immediate physical danger. It cannot replace emergency medical response.

If you remember one thing

ADHD in women is neither a trend nor a hidden answer to every struggle. It is a developmental pattern that deserves a careful history.

The most useful evaluation stays curious. It looks for ADHD, anxiety, depression, trauma, sleep problems, medical causes, and combinations. It treats the person, not a stereotype.

You do not need to prove you struggled loudly. You do deserve an assessment that takes the full timeline seriously.

The rest of this series

Ten guides on women’s mental health, written to be read in any order. Each one owns its own question, so none of them repeats another.

• Start with the map: The Mental Health Timeline Every Woman Should Know
• PMDD, PMS, and premenstrual exacerbation
• Postpartum depression, anxiety, OCD, and psychosis warning signs
• Maternal burnout, depression, and sensory overload
• Perimenopause: anxiety, mood, and brain fog
• Hidden anxiety and depression behind outward success
• You are here: When adult ADHD looks like anxiety or depression
• Women, anxiety, hormones, insomnia, and sleep disorders
• Trauma or personality? Understanding adult patterns
• Repeating relationship patterns: attachment, trauma, and online labels

Education disclaimer

This article is for general education. It cannot diagnose you, replace an evaluation, or give personal medical advice. Reading NPFady.com does not create a clinician-patient relationship. Do not start, stop, or change medication or hormone treatment without the clinician who knows your history.

References

1. Centers for Disease Control and Prevention. ADHD in Adults. Updated public clinical overview. https://www.cdc.gov/adhd/about/adhd-in-adults.html. Accessed 2026-08-15.
2. Adamou M, et al. The adult ADHD assessment quality assurance standard. Front Psychiatry. 2024;15:1380410. PMID 39156609. PMCID PMC11327143. doi:10.3389/fpsyt.2024.1380410. https://pmc.ncbi.nlm.nih.gov/articles/PMC11327143/
3. Young S, Adamo N, Ásgeirsdóttir BB, et al. Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/hyperactivity disorder in girls and women. BMC Psychiatry. 2020;20:404. PMID 32787804. PMCID PMC7422602. doi:10.1186/s12888-020-02707-9. https://pmc.ncbi.nlm.nih.gov/articles/PMC7422602/
4. Hinshaw SP, et al. Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. J Child Psychol Psychiatry. 2022;63:484–496. PMID 34231220. doi:10.1111/jcpp.13480. https://pubmed.ncbi.nlm.nih.gov/34231220/
5. Centers for Disease Control and Prevention. Diagnosing ADHD. https://www.cdc.gov/adhd/diagnosis/index.html. Accessed 2026-08-15.
6. U.S. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. May 11, 2023. https://www.fda.gov/drugs/drug-safety-communications/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions. Accessed 2026-08-15.
7. U.S. Food and Drug Administration. SIMTRIYO (centanafadine) regulatory record. Novel Drug Approvals 2026: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026. Approval letter dated July 24, 2026: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/218145Orig1s000ltr.pdf. Prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218145s000lbl.pdf. Otsuka scheduling/commercial-status statement: https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine. Accessed 2026-08-15.
8. Callan PD, Swanberg S, Weber SK, et al. Diagnostic Utility of Conners Continuous Performance Test-3 for Attention Deficit/Hyperactivity Disorder: A Systematic Review. J Atten Disord. 2024;28:992–1007. PMID 38317541. doi:10.1177/10870547231223727. https://pubmed.ncbi.nlm.nih.gov/38317541/
9. Osianlis E, Thomas EHX, Jenkins LM, Gurvich C. ADHD and Sex Hormones in Females: A Systematic Review. J Atten Disord. 2025;29:706–723. PMID 40251875. PMCID PMC12145478. doi:10.1177/10870547251332319. https://pmc.ncbi.nlm.nih.gov/articles/PMC12145478/
10. Ostinelli EG, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis. Lancet Psychiatry. 2025;12:32–43. PMID 39701638. doi:10.1016/S2215-0366(24)00360-2. https://pubmed.ncbi.nlm.nih.gov/39701638/
11. Liu Y, Zhu F, Yu Y, et al. A meta-analysis of the intervention effect of cognitive behavioral therapy on adult ADHD. J Affect Disord. 2026;399:121107. PMID 41483880. doi:10.1016/j.jad.2025.121107. https://pubmed.ncbi.nlm.nih.gov/41483880/
12. Farhat LC, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025;12:355–365. PMID 40203844. doi:10.1016/S2215-0366(25)00062-8. https://pubmed.ncbi.nlm.nih.gov/40203844/
13. Huybrechts KF, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium. JAMA Psychiatry. 2018;75:167–175. PMID 29238795. PMCID PMC5838573. doi:10.1001/jamapsychiatry.2017.3644. https://pubmed.ncbi.nlm.nih.gov/29238795/
14. Cohen JM, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017;130:1192–1201. PMID 29112657. PMCID PMC5709205. doi:10.1097/AOG.0000000000002362. https://pmc.ncbi.nlm.nih.gov/articles/PMC5709205/
15. Bang Madsen K, Robakis TK, Liu X, et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;28(4):1739–1746. PMID 36759544. doi:10.1038/s41380-023-01992-6. https://pubmed.ncbi.nlm.nih.gov/36759544/
16. Suarez EA, et al. Prescription stimulant use during pregnancy and risk of neurodevelopmental disorders in children. JAMA Psychiatry. 2024;81:477–488. PMID 38265792. PMCID PMC10809143. doi:10.1001/jamapsychiatry.2023.5073. https://pmc.ncbi.nlm.nih.gov/articles/PMC10809143/
17. MotherToBaby. Methylphenidate. Fact sheet updated February 2026. https://www.ncbi.nlm.nih.gov/books/NBK582838/. Accessed 2026-08-15.
18. Drugs and Lactation Database (LactMed). Atomoxetine. Revised June 15, 2026. https://www.ncbi.nlm.nih.gov/books/NBK501732/. Accessed 2026-08-15.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.